Amarin stock tumble: No respect or justified jitters?
This article was originally published in Scrip
Executive Summary
Shares of Amarin tumbled for the third day likely over investors’ concerns about the future of the company's newly approved fish oil pill Vascepa (formerly AMR101), a semisynthetic, 96% ultra-pure ethyl ester of eicosapentaenoic acid, which gained the US FDA's OK on 26 July as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia, or very high triglycerides, 500mg/dL or above.